| 產(chǎn)品編號 | bsm-33052M |
| 英文名稱 | Mouse Anti-CD45 antibody |
| 中文名稱 | 白細胞共同抗原CD45單克隆抗體 |
| 別 名 | B220; CD 45; CD-45; CD45; cd45 antigen; ec3.1.3.48; CD45R; GP180; GP180; GP 180; L CA; LCA; L-CA; Leukocyte common antigen; LY5; Ly-5 glycoprotein; Protein tyrosine phosphatase receptor type C; Protein tyrosine phosphatase receptor type c polypeptide; protein tyrosine phosphatase, receptor type, C; Receptor-type tyrosine-protein phosphatase C; PTPRC; PTPRC_HUMAN; SCID due to PTPRC deficiency; T200; T200 glycoprotein; T200 leukocyte common antigen; Human homolog of severe combined immunodeficiency due to PTPRC deficiency. |
 |
Specific References (1) | bsm-33052M has been referenced in 1 publications.
[IF=6.799] Smriti Arora. et al. Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors. Lab Chip. 2022 Feb;: IHC ; Human.
|
| 研究領(lǐng)域 | 細胞生物 免疫學 神經(jīng)生物學 信號轉(zhuǎn)導 干細胞 細胞表面分子 糖蛋白 細胞類型標志物 自然殺傷細胞 淋巴細胞 t-淋巴細胞 b-淋巴細胞 跨膜蛋白 細胞膜蛋白 |
| 抗體來源 | Mouse |
| 克隆類型 | Monoclonal |
| 克 隆 號 | 14A9 |
| 交叉反應 | Human |
| 產(chǎn)品應用 | WB=1:500-1000,Flow-Cyt=1:50,ELISA=1:1000-5000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 143kDa |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | Recombinant human CD45 |
| 亞 型 | IgG1 |
| 純化方法 | affinity purified by Protein G |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
The protein encoded by this gene is a member of the protein tyrosine phosphatase (PTP) family. PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. This PTP contains an extracellular domain, a single transmembrane segment and two tandem intracytoplasmic catalytic domains, and thus belongs to receptor type PTP. This gene is specifically expressed in hematopoietic cells. This PTP has been shown to be an essential regulator of T- and B-cell antigen receptor signaling. It functions through either direct interaction with components of the antigen receptor complexes, or by activating various Src family kinases required for the antigen receptor signaling. This PTP also suppresses JAK kinases, and thus functions as a regulator of cytokine receptor signaling. Four alternatively spliced transcripts variants of this gene, which encode distinct isoforms, have been reported. [provided by RefSeq, Jul 2008]. Function: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN. Dephosphorylates LYN, and thereby modulates LYN activity. Subunit: Binds GANAB and PRKCSH. Interacts with SKAP1. Interacts with DPP4; the interaction is enhanced in a interleukin-12-dependent manner in activated lymphocytes. Subcellular Location: Membrane; Single-pass type I membrane protein. Membrane raft. Note=Colocalized with DPP4 in membrane rafts. Post-translational modifications: Heavily N- and O-glycosylated. DISEASE: Defects in PTPRC are a cause of severe combined immunodeficiency autosomal recessive T-cell-negative/B-cell-positive/NK-cell-positive (T(-)B(+)NK(+) SCID) [MIM:608971]. A form of severe combined immunodeficiency (SCID), a genetically and clinically heterogeneous group of rare congenital disorders characterized by impairment of both humoral and cell-mediated immunity, leukopenia, and low or absent antibody levels. Patients present in infancy recurrent, persistent infections by opportunistic organisms. The common characteristic of all types of SCID is absence of T-cell-mediated cellular immunity due to a defect in T-cell development. Genetic variations in PTPRC are involved in multiple sclerosis susceptibility (MS) [MIM:126200]. MS is a neurodegenerative disorder characterized by the gradual accumulation of focal plaques of demyelination particularly in the periventricular areas of the brain. Peripheral nerves are not affected. Onset usually in third or fourth decade with intermittent progression over an extended period. The cause is still uncertain. Similarity: Belongs to the protein-tyrosine phosphatase family. Receptor class 1/6 subfamily. Contains 2 fibronectin type-III domains. Contains 2 tyrosine-protein phosphatase domains. SWISS: P08575 Gene ID: 5788 Database links: Entrez Gene: 5788 Human Entrez Gene: 19264 Mouse Omim: 151460 Human SwissProt: P08575 Human SwissProt: P06800 Mouse Unigene: 654514 Human Unigene: 391573 Mouse Unigene: 90166 Rat |
| 產(chǎn)品圖片 |
Sample:
Lane 1: Molt-4 (Human) Cell Lysate at 30 ug
Lane 2: K562 (Human) Cell Lysate at 30 ug
Primary: Anti-CD45 (bsm-33052M) at 1/1000 dilution
Secondary: IRDye800CW Goat Anti-Mouse IgG at 1/20000 dilution
Predicted band size: 220 kD
Observed band size: 220 kD
Blank control:U937.
Primary Antibody (green line): Mouse Anti-CD45 antibody (bsm-33052M)
Dilution: 1:50;
Secondary Antibody : Goat anti-mouse IgG-FITC
Dilution: 0.5ug/Test.
Protocol
The cells were incubated in 5%BSA to block non-specific protein-protein interactions for 30 min at room temperature .Cells stained with Primary Antibody for 30 min at room temperature. The secondary antibody used for 40 min at room temperature. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關(guān)于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
